Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838708 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus
A Phase 2 study of Pruritus, Atopic Dermatitis, sponsored by Serentis.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 13
- Study locations
NCT00838708 is a Phase 2 study of Pruritus, Atopic Dermatitis that has completed, run by Serentis. The registered enrollment target is 62 participants. The trial reports 13 study locations across 10 states.
The verdict
NCT00838708, a Phase 2 study of Pruritus, Atopic Dermatitis, has completed, sponsored by Serentis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 13
- Study locations
Study Summary
Pruritus is an essential feature for the diagnosis of atopic dermatitis and may play an important part in disease progression. Itching has a significant impact on the quality of life of AD sufferers, in particular night-time itching leading to sleep disturbance and subsequent poor daytime performance. The objective of this study is to determine whether SRD174 Cream is a safe and effective therapy for moderate to severe pruritus associated with atopic dermatitis.
Conditions Studied
Interventions
- DRUG SRD174 Cream
- OTHER vehicle cream
Study Locations (13)
Michigan
- - Detroit
- - Grand Blanc
North Carolina
- - High Point
- - Winston-Salem
Pennsylvania
- - Hazleton
- - Philadelphia
Alabama
- - Birmingham
Arkansas
- - Hot Springs
California
- - Oceanside
Florida
- - Ormond Beach
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00838708
The ClinicalTrials.gov registry entry for NCT00838708 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Serentis, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pruritus, Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which SRD174 Cream is the first listed.
NCT00838708 reports 13 study locations spanning 10 distinct geographic areas - top geographies include Michigan, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00838708 about?
NCT00838708 is a clinical study titled "Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus". Pruritus is an essential feature for the diagnosis of atopic dermatitis and may play an important part in disease progression. Itching has a significant impact on the quality of life of AD sufferers, in particular night-time itching leading to sleep disturbance and subsequent poor daytime performanc...
What is the current status of trial NCT00838708?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2009-01. Estimated completion is 2009-08.
What conditions does trial NCT00838708 study?
This clinical trial studies the following conditions: Pruritus, Atopic Dermatitis.
What interventions are being tested in trial NCT00838708?
The interventions under investigation include: SRD174 Cream (DRUG), vehicle cream (OTHER).
Who is sponsoring clinical trial NCT00838708?
This trial is sponsored by Serentis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00838708 being conducted?
This trial has 13 study locations across Alabama, Arkansas, California, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.